Stock Track | Teva Pharmaceutical Soars 5.15% in Pre-Market Trading on Q2 Revenue Beat and Guidance

Stock Track

07/29

Teva Pharmaceutical's stock surged 5.15% in pre-market trading after the company released second-quarter earnings that topped revenue forecasts and reaffirmed its full-year guidance.

The company reported quarterly revenue of $4.142 billion, surpassing the analyst consensus of $4.047 billion. Adjusted earnings per share, however, came in at just $0.02, missing the $0.25 estimate by a wide margin. Nevertheless, investors appeared to focus on the top-line strength and the company's outlook. Teva expects 2026 revenue to be in the range of $16.5 billion to $16.85 billion, with adjusted EPS between $1.91 and $2.11.

The positive reaction suggests that the market is rewarding the revenue beat and the maintained guidance, despite the considerable earnings miss, as the company continues to advance its pipeline and biosimilar portfolio.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1197626086"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197626086\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197626086?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197626086","market":"sg","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical Soars 5.15% in Pre-Market Trading on Q2 Revenue Beat and Guidance","media":"Stock Track","content":"<p>Teva Pharmaceutical's stock surged 5.15% in pre-market trading after the company released second-quarter earnings that topped revenue forecasts and reaffirmed its full-year guidance.</p>\n        <p>The company reported quarterly revenue of $4.142 billion, surpassing the analyst consensus of $4.047 billion. Adjusted earnings per share, however, came in at just $0.02, missing the $0.25 estimate by a wide margin. Nevertheless, investors appeared to focus on the top-line strength and the company's outlook. Teva expects 2026 revenue to be in the range of $16.5 billion to $16.85 billion, with adjusted EPS between $1.91 and $2.11.</p>\n        <p>The positive reaction suggests that the market is rewarding the revenue beat and the maintained guidance, despite the considerable earnings miss, as the company continues to advance its pipeline and biosimilar portfolio.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Teva Pharmaceutical Soars 5.15% in Pre-Market Trading on Q2 Revenue Beat and Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical Soars 5.15% in Pre-Market Trading on Q2 Revenue Beat and Guidance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-07-29 19:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Teva Pharmaceutical's stock surged 5.15% in pre-market trading after the company released second-quarter earnings that topped revenue forecasts and reaffirmed its full-year guidance.</p>\n        <p>The company reported quarterly revenue of $4.142 billion, surpassing the analyst consensus of $4.047 billion. Adjusted earnings per share, however, came in at just $0.02, missing the $0.25 estimate by a wide margin. Nevertheless, investors appeared to focus on the top-line strength and the company's outlook. Teva expects 2026 revenue to be in the range of $16.5 billion to $16.85 billion, with adjusted EPS between $1.91 and $2.11.</p>\n        <p>The positive reaction suggests that the market is rewarding the revenue beat and the maintained guidance, despite the considerable earnings miss, as the company continues to advance its pipeline and biosimilar portfolio.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦製藥","start_time":0,"source_url":"","article_id":"1197626086","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197626086","pubTimestamp":1785323449,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Teva Pharmaceutical's stock surged 5.15% in pre-market trading after the company released second-quarter earnings that topped revenue forecasts and reaffirmed its full-year guidance.         The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"股票跟踪 | 梯瓦制药在第二季度收入预期和指引的盘前交易中飙升 5.15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical's stock surged 5.15% in pre-market trading after the company released second-quarter earnings that topped revenue forecasts and reaffirmed its full-year guidance.\nThe company reported quarterly revenue of $4.142 billion, surpassing the analyst consensus of $4.047 billion. Adjusted earnings per share, however, came in at just $0.02, missing the $0.25 estimate by a wide margin. Nevertheless, investors appeared to focus on the top-line strength and the company's outlook. Teva expects 2026 revenue to be in the range of $16.5 billion to $16.85 billion, with adjusted EPS between $1.91 and $2.11.\nThe positive reaction suggests that the market is rewarding the revenue beat and the maintained guidance, despite the considerable earnings miss, as the company continues to advance its pipeline and biosimilar portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}